M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation
We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PYK with an IC50 value of 0....
Uloženo v:
| Vydáno v: | Proceedings of the National Academy of Sciences - PNAS Ročník 110; číslo 15; s. 5881 |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
09.04.2013
|
| Témata: | |
| ISSN: | 1091-6490, 1091-6490 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PYK with an IC50 value of 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric form of M2PYK with an IC50 of 78 nM. The allosteric activator fructose-1,6-bisphosphate [F16BP, AC50 (concentration that gives 50% activation) of 7 μM] shifts the equilibrium to the tetrameric active R-state, which has a similar activity to that of the constitutively fully active isoform M1PYK. Proliferation assays using HCT-116 cells showed that addition of inhibitors phenylalanine and T3 both increased cell proliferation, whereas addition of the activator F16BP reduced proliferation. F16BP abrogates the inhibitory effect of both phenylalanine and T3, highlighting a dominant role of M2PYK allosteric activation in the regulation of cancer proliferation. X-ray structures show constitutively fully active M1PYK and F16BP-bound M2PYK in an R-state conformation with a lysine at the dimer-interface acting as a peg in a hole, locking the active tetramer conformation. Binding of phenylalanine in an allosteric pocket induces a 13° rotation of the protomers, destroying the peg-in-hole R-state interface. This distinct T-state tetramer is stabilized by flipped out Trp/Arg side chains that stack across the dimer interface. X-ray structures and biophysical binding data of M2PYK complexes explain how, at a molecular level, fluctuations in concentrations of amino acids, thyroid hormone, and glucose metabolites switch M2PYK on and off to provide the cell with a nutrient sensing and growth signaling mechanism. |
|---|---|
| AbstractList | We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PYK with an IC50 value of 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric form of M2PYK with an IC50 of 78 nM. The allosteric activator fructose-1,6-bisphosphate [F16BP, AC50 (concentration that gives 50% activation) of 7 μM] shifts the equilibrium to the tetrameric active R-state, which has a similar activity to that of the constitutively fully active isoform M1PYK. Proliferation assays using HCT-116 cells showed that addition of inhibitors phenylalanine and T3 both increased cell proliferation, whereas addition of the activator F16BP reduced proliferation. F16BP abrogates the inhibitory effect of both phenylalanine and T3, highlighting a dominant role of M2PYK allosteric activation in the regulation of cancer proliferation. X-ray structures show constitutively fully active M1PYK and F16BP-bound M2PYK in an R-state conformation with a lysine at the dimer-interface acting as a peg in a hole, locking the active tetramer conformation. Binding of phenylalanine in an allosteric pocket induces a 13° rotation of the protomers, destroying the peg-in-hole R-state interface. This distinct T-state tetramer is stabilized by flipped out Trp/Arg side chains that stack across the dimer interface. X-ray structures and biophysical binding data of M2PYK complexes explain how, at a molecular level, fluctuations in concentrations of amino acids, thyroid hormone, and glucose metabolites switch M2PYK on and off to provide the cell with a nutrient sensing and growth signaling mechanism.We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PYK with an IC50 value of 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric form of M2PYK with an IC50 of 78 nM. The allosteric activator fructose-1,6-bisphosphate [F16BP, AC50 (concentration that gives 50% activation) of 7 μM] shifts the equilibrium to the tetrameric active R-state, which has a similar activity to that of the constitutively fully active isoform M1PYK. Proliferation assays using HCT-116 cells showed that addition of inhibitors phenylalanine and T3 both increased cell proliferation, whereas addition of the activator F16BP reduced proliferation. F16BP abrogates the inhibitory effect of both phenylalanine and T3, highlighting a dominant role of M2PYK allosteric activation in the regulation of cancer proliferation. X-ray structures show constitutively fully active M1PYK and F16BP-bound M2PYK in an R-state conformation with a lysine at the dimer-interface acting as a peg in a hole, locking the active tetramer conformation. Binding of phenylalanine in an allosteric pocket induces a 13° rotation of the protomers, destroying the peg-in-hole R-state interface. This distinct T-state tetramer is stabilized by flipped out Trp/Arg side chains that stack across the dimer interface. X-ray structures and biophysical binding data of M2PYK complexes explain how, at a molecular level, fluctuations in concentrations of amino acids, thyroid hormone, and glucose metabolites switch M2PYK on and off to provide the cell with a nutrient sensing and growth signaling mechanism. We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally occurring small-molecule metabolites. Phenylalanine stabilizes an inactive T-state tetrameric conformer and inhibits M2PYK with an IC50 value of 0.24 mM, whereas thyroid hormone (triiodo-L-thyronine, T3) stabilizes an inactive monomeric form of M2PYK with an IC50 of 78 nM. The allosteric activator fructose-1,6-bisphosphate [F16BP, AC50 (concentration that gives 50% activation) of 7 μM] shifts the equilibrium to the tetrameric active R-state, which has a similar activity to that of the constitutively fully active isoform M1PYK. Proliferation assays using HCT-116 cells showed that addition of inhibitors phenylalanine and T3 both increased cell proliferation, whereas addition of the activator F16BP reduced proliferation. F16BP abrogates the inhibitory effect of both phenylalanine and T3, highlighting a dominant role of M2PYK allosteric activation in the regulation of cancer proliferation. X-ray structures show constitutively fully active M1PYK and F16BP-bound M2PYK in an R-state conformation with a lysine at the dimer-interface acting as a peg in a hole, locking the active tetramer conformation. Binding of phenylalanine in an allosteric pocket induces a 13° rotation of the protomers, destroying the peg-in-hole R-state interface. This distinct T-state tetramer is stabilized by flipped out Trp/Arg side chains that stack across the dimer interface. X-ray structures and biophysical binding data of M2PYK complexes explain how, at a molecular level, fluctuations in concentrations of amino acids, thyroid hormone, and glucose metabolites switch M2PYK on and off to provide the cell with a nutrient sensing and growth signaling mechanism. |
| Author | Fothergill-Gilmore, Linda A Walkinshaw, Malcolm D Wear, Martin A O'Neill, J Robert Morgan, Hugh P O'Reilly, Francis J Hupp, Ted |
| Author_xml | – sequence: 1 givenname: Hugh P surname: Morgan fullname: Morgan, Hugh P organization: Centre for Translational and Chemical Biology, University of Edinburgh, Edinburgh EH9 3JR, United Kingdom – sequence: 2 givenname: Francis J surname: O'Reilly fullname: O'Reilly, Francis J – sequence: 3 givenname: Martin A surname: Wear fullname: Wear, Martin A – sequence: 4 givenname: J Robert surname: O'Neill fullname: O'Neill, J Robert – sequence: 5 givenname: Linda A surname: Fothergill-Gilmore fullname: Fothergill-Gilmore, Linda A – sequence: 6 givenname: Ted surname: Hupp fullname: Hupp, Ted – sequence: 7 givenname: Malcolm D surname: Walkinshaw fullname: Walkinshaw, Malcolm D |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23530218$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1Lw0AQxRep2A89e5M9ekmd2a8kRyl-QcWLnsMm2a2ryabuJoX-96ZaQXgww-Pxm-HNycR33hByibBESPnN1uu4RIYpyhQRTsgMIcdEiRwm__Ypmcf4AQC5zOCMTBmXHBhmM6KfGd3uw7DTvaGfbsQZug3dztUmUk1bU71r72JLbReoH_rgjO9pND46v6Ha1zSYzdDo3nWedpZWpmkOgMZZE37cc3JqdRPNxXEuyNv93evqMVm_PDytbtdJJXPok8qmqlQyR86kxVEWpEix0rJEsKjQchBcSTCCqUxIXVqZqVpqSGWl85QtyPUvd7z-NZjYF62Lh3e0N90QixGsUHApxBi9OkaHsjV1sQ2u1WFf_NXCvgF_aGao |
| CitedBy_id | crossref_primary_10_1002_1873_3468_13648 crossref_primary_10_1073_pnas_1704145115 crossref_primary_10_1002_ijc_32756 crossref_primary_10_1016_j_bbcan_2019_01_004 crossref_primary_10_3390_ijms232113172 crossref_primary_10_1021_jacs_8b10538 crossref_primary_10_1007_s00408_025_00821_7 crossref_primary_10_3389_fimmu_2021_748573 crossref_primary_10_3389_fphar_2022_1009229 crossref_primary_10_1002_humu_23239 crossref_primary_10_1002_bies_201400108 crossref_primary_10_1016_j_ygcen_2015_07_006 crossref_primary_10_1016_j_yjmcc_2016_01_009 crossref_primary_10_1107_S0907444913013875 crossref_primary_10_15252_embr_201643300 crossref_primary_10_1016_j_molbiopara_2020_111263 crossref_primary_10_1016_j_athoracsur_2019_01_076 crossref_primary_10_1128_msystems_01131_24 crossref_primary_10_1186_s10020_025_01320_4 crossref_primary_10_1016_j_copbio_2017_03_022 crossref_primary_10_1007_s13238_015_0132_x crossref_primary_10_2147_DMSO_S366403 crossref_primary_10_1074_jbc_M113_508127 crossref_primary_10_1016_j_jbc_2023_104892 crossref_primary_10_1016_j_bbcan_2014_07_008 crossref_primary_10_1038_s41467_017_02086_y crossref_primary_10_1371_journal_pbio_2004413 crossref_primary_10_1002_cbic_202200339 crossref_primary_10_1016_j_chembiol_2018_03_002 crossref_primary_10_1042_BCJ20180171 crossref_primary_10_1002_pro_2299 crossref_primary_10_3390_ijms22031171 crossref_primary_10_4155_fmc_2023_0216 crossref_primary_10_1002_chem_202402534 crossref_primary_10_1074_jbc_RA120_013030 crossref_primary_10_1016_j_heliyon_2024_e27361 crossref_primary_10_3390_jpm15020050 crossref_primary_10_7554_eLife_92741_4 crossref_primary_10_1007_s13238_015_0146_4 crossref_primary_10_1111_febs_14175 crossref_primary_10_1007_s13105_024_01007_0 crossref_primary_10_1002_prot_25272 crossref_primary_10_1016_j_gendis_2024_101491 crossref_primary_10_1016_j_freeradbiomed_2019_08_007 crossref_primary_10_1016_j_canlet_2014_01_031 crossref_primary_10_1038_s42003_019_0343_4 crossref_primary_10_1111_febs_16191 crossref_primary_10_1038_srep15171 crossref_primary_10_1158_0008_5472_CAN_20_4190 crossref_primary_10_1038_s41419_018_1271_9 crossref_primary_10_1080_14756366_2017_1404591 crossref_primary_10_1107_S2053230X19007209 crossref_primary_10_3390_ijms23020775 crossref_primary_10_1016_j_jmb_2024_168708 crossref_primary_10_3390_nu15030577 crossref_primary_10_1007_s13402_018_0383_7 crossref_primary_10_1038_s41467_024_51875_9 crossref_primary_10_1016_j_chembiol_2014_08_007 crossref_primary_10_1016_j_bpj_2015_05_040 crossref_primary_10_1042_BCJ20180556 crossref_primary_10_1002_advs_202305662 crossref_primary_10_1002_bies_201900194 crossref_primary_10_1016_j_tibtech_2016_04_012 crossref_primary_10_1016_j_molcel_2015_07_013 crossref_primary_10_1016_j_bbrc_2020_08_048 crossref_primary_10_1016_j_freeradbiomed_2024_08_012 crossref_primary_10_1016_j_phrs_2025_107840 crossref_primary_10_1016_j_bbapap_2019_140296 crossref_primary_10_1016_j_jinorgbio_2021_111606 crossref_primary_10_1073_pnas_2306525120 crossref_primary_10_1186_s12938_019_0637_2 crossref_primary_10_3390_cells9122600 crossref_primary_10_1038_s41467_021_21960_4 crossref_primary_10_3390_biomedicines12122916 crossref_primary_10_7554_eLife_92741 crossref_primary_10_1098_rsob_130232 crossref_primary_10_3389_fmed_2023_1151359 crossref_primary_10_1038_s41419_024_07159_7 crossref_primary_10_3389_fimmu_2025_1588019 crossref_primary_10_1016_j_semcdb_2015_08_004 crossref_primary_10_3389_fimmu_2016_00145 crossref_primary_10_3390_cancers16132290 crossref_primary_10_7554_eLife_45068 crossref_primary_10_1016_j_bpc_2021_106701 crossref_primary_10_3390_metabo15030203 crossref_primary_10_1111_bpa_12311 crossref_primary_10_1016_j_jbc_2024_107538 crossref_primary_10_1038_s44318_024_00110_8 crossref_primary_10_1042_BJ20130790 crossref_primary_10_1039_D1SC00929J crossref_primary_10_1177_1533034617749418 crossref_primary_10_1016_j_biopha_2016_10_108 crossref_primary_10_1111_brv_12140 crossref_primary_10_1016_j_bmc_2017_05_004 crossref_primary_10_1074_jbc_RA120_015800 crossref_primary_10_1016_j_clinre_2019_06_008 crossref_primary_10_1042_BCJ20200656 crossref_primary_10_1016_j_jbc_2024_107648 crossref_primary_10_3389_fimmu_2019_02919 crossref_primary_10_1039_C4MT00165F crossref_primary_10_1016_j_ibmb_2018_12_010 crossref_primary_10_1002_pro_3691 crossref_primary_10_1371_journal_pone_0134049 crossref_primary_10_1016_j_jmb_2025_169176 crossref_primary_10_1038_s41598_017_18098_z crossref_primary_10_1371_journal_pcbi_1008708 crossref_primary_10_7554_eLife_59166 crossref_primary_10_1039_D4MH00470A crossref_primary_10_1098_rsos_140120 crossref_primary_10_1016_j_molstruc_2024_141062 crossref_primary_10_1039_D4MD00367E crossref_primary_10_1111_mec_12534 crossref_primary_10_1016_j_ejmech_2019_03_003 crossref_primary_10_1016_j_jorganchem_2022_122338 crossref_primary_10_3390_ijerph182111225 crossref_primary_10_1371_journal_pone_0098756 crossref_primary_10_3390_cancers15010265 crossref_primary_10_1186_s12929_025_01170_6 crossref_primary_10_3390_cells10092489 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1073/pnas.1217157110 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 1091-6490 |
| ExternalDocumentID | 23530218 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 094417/Z/10/Z – fundername: Medical Research Council – fundername: Wellcome Trust grantid: 092076 – fundername: Biotechnology and Biological Sciences Research Council |
| GroupedDBID | --- -DZ -~X .55 0R~ 123 29P 2AX 2FS 2WC 4.4 53G 5RE 5VS 85S AACGO AAFWJ AANCE ABBHK ABOCM ABPLY ABPPZ ABTLG ABXSQ ABZEH ACGOD ACHIC ACIWK ACNCT ACPRK ADQXQ ADULT ADXHL AENEX AEUPB AEXZC AFFNX AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS AQVQM BKOMP CGR CS3 CUY CVF D0L DCCCD DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HH5 HYE IPSME JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST KQ8 L7B LU7 MVM N9A NPM N~3 O9- OK1 PNE PQQKQ R.V RHI RNA RNS RPM RXW SA0 SJN TAE TN5 UKR W8F WH7 WOQ WOW X7M XSW Y6R YBH YKV YSK ZCA ~02 ~KM 7X8 |
| ID | FETCH-LOGICAL-c590t-cf76b6591325f15f1f05471ca5b10f161f3043650e426845abf586d5a075ca972 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 141 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000317537900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1091-6490 |
| IngestDate | Thu Oct 02 05:24:41 EDT 2025 Mon Jul 21 06:00:52 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 15 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c590t-cf76b6591325f15f1f05471ca5b10f161f3043650e426845abf586d5a075ca972 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://www.pnas.org/content/110/15/5881 |
| PMID | 23530218 |
| PQID | 1326143544 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1326143544 pubmed_primary_23530218 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-04-09 |
| PublicationDateYYYYMMDD | 2013-04-09 |
| PublicationDate_xml | – month: 04 year: 2013 text: 2013-04-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Proceedings of the National Academy of Sciences - PNAS |
| PublicationTitleAlternate | Proc Natl Acad Sci U S A |
| PublicationYear | 2013 |
| References | 9990017 - Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1291-6 21982705 - Cell Metab. 2011 Oct 5;14(4):443-51 12820363 - Anticancer Res. 2003 Mar-Apr;23(2A):1149-54 20051527 - Endocr Rev. 2010 Apr;31(2):139-70 16634623 - Biochemistry. 2006 May 2;45(17):5421-9 22922757 - Nat Chem Biol. 2012 Oct;8(10):839-47 9854017 - Biochem J. 1999 Jan 1;337 ( Pt 1):1-11 20017496 - J Med Chem. 2010 Feb 11;53(3):1048-55 19924905 - Biochemistry. 2009 Dec 29;48(51):12242-51 20156581 - Int J Biochem Cell Biol. 2011 Jul;43(7):969-80 21789790 - Oncotarget. 2011 May;2(5):393-400 7810732 - Am J Physiol. 1994 Dec;267(6 Pt 2):H2325-32 15996096 - Biochemistry. 2005 Jul 12;44(27):9417-29 22052977 - Science. 2011 Dec 2;334(6060):1278-83 21700219 - Mol Cell. 2011 Jun 24;42(6):719-30 1854723 - Biochemistry. 1991 Jul 23;30(29):7105-11 2605219 - Biochemistry. 1989 Oct 31;28(22):8756-64 17308100 - Cancer Res. 2007 Feb 15;67(4):1602-8 5911499 - Am J Pathol. 1966 Aug;49(2):309-24 18337823 - Nature. 2008 Mar 13;452(7184):230-3 2813362 - Proc Natl Acad Sci U S A. 1989 Oct;86(20):7861-5 20123988 - J Biol Chem. 2010 Apr 23;285(17):12892-8 20358419 - Tumour Biol. 2010 Apr;31(2):69-77 6606587 - Fed Proc. 1984 Jan;43(1):116-20 20451379 - Bioorg Med Chem Lett. 2010 Jun 1;20(11):3387-93 22807066 - IUBMB Life. 2012 Sep;64(9):775-82 11336658 - Biochem J. 2001 May 15;356(Pt 1):247-56 16977383 - Inflamm Res. 2006 Aug;55(8):354-8 21958545 - Bioorg Med Chem Lett. 2011 Nov 1;21(21):6322-7 21620138 - Cell. 2011 May 27;145(5):732-44 1532331 - Crit Rev Oncog. 1992;3(1-2):91-115 20005212 - Biochem Pharmacol. 2010 Apr 15;79(8):1118-24 4455196 - Biochem J. 1974 Jul;141(1):127-31 19460998 - Science. 2009 May 22;324(5930):1029-33 21945435 - Biochem Biophys Res Commun. 2011 Oct 14;414(1):73-8 1885610 - J Biol Chem. 1991 Sep 5;266(25):16842-6 9572839 - Biochemistry. 1998 May 5;37(18):6247-55 23064226 - Nature. 2012 Nov 15;491(7424):458-62 18337815 - Nature. 2008 Mar 13;452(7184):181-6 19920251 - Sci Signal. 2009;2(97):ra73 5912613 - J Natl Cancer Inst. 1966 Aug;37(2):185-90 |
| References_xml | – reference: 6606587 - Fed Proc. 1984 Jan;43(1):116-20 – reference: 16977383 - Inflamm Res. 2006 Aug;55(8):354-8 – reference: 20156581 - Int J Biochem Cell Biol. 2011 Jul;43(7):969-80 – reference: 1885610 - J Biol Chem. 1991 Sep 5;266(25):16842-6 – reference: 18337815 - Nature. 2008 Mar 13;452(7184):181-6 – reference: 22922757 - Nat Chem Biol. 2012 Oct;8(10):839-47 – reference: 9854017 - Biochem J. 1999 Jan 1;337 ( Pt 1):1-11 – reference: 9990017 - Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1291-6 – reference: 21700219 - Mol Cell. 2011 Jun 24;42(6):719-30 – reference: 11336658 - Biochem J. 2001 May 15;356(Pt 1):247-56 – reference: 20017496 - J Med Chem. 2010 Feb 11;53(3):1048-55 – reference: 20358419 - Tumour Biol. 2010 Apr;31(2):69-77 – reference: 18337823 - Nature. 2008 Mar 13;452(7184):230-3 – reference: 4455196 - Biochem J. 1974 Jul;141(1):127-31 – reference: 12820363 - Anticancer Res. 2003 Mar-Apr;23(2A):1149-54 – reference: 21958545 - Bioorg Med Chem Lett. 2011 Nov 1;21(21):6322-7 – reference: 5911499 - Am J Pathol. 1966 Aug;49(2):309-24 – reference: 2813362 - Proc Natl Acad Sci U S A. 1989 Oct;86(20):7861-5 – reference: 20051527 - Endocr Rev. 2010 Apr;31(2):139-70 – reference: 22052977 - Science. 2011 Dec 2;334(6060):1278-83 – reference: 2605219 - Biochemistry. 1989 Oct 31;28(22):8756-64 – reference: 21945435 - Biochem Biophys Res Commun. 2011 Oct 14;414(1):73-8 – reference: 22807066 - IUBMB Life. 2012 Sep;64(9):775-82 – reference: 21789790 - Oncotarget. 2011 May;2(5):393-400 – reference: 1854723 - Biochemistry. 1991 Jul 23;30(29):7105-11 – reference: 17308100 - Cancer Res. 2007 Feb 15;67(4):1602-8 – reference: 5912613 - J Natl Cancer Inst. 1966 Aug;37(2):185-90 – reference: 15996096 - Biochemistry. 2005 Jul 12;44(27):9417-29 – reference: 23064226 - Nature. 2012 Nov 15;491(7424):458-62 – reference: 20005212 - Biochem Pharmacol. 2010 Apr 15;79(8):1118-24 – reference: 16634623 - Biochemistry. 2006 May 2;45(17):5421-9 – reference: 9572839 - Biochemistry. 1998 May 5;37(18):6247-55 – reference: 19460998 - Science. 2009 May 22;324(5930):1029-33 – reference: 19924905 - Biochemistry. 2009 Dec 29;48(51):12242-51 – reference: 20123988 - J Biol Chem. 2010 Apr 23;285(17):12892-8 – reference: 19920251 - Sci Signal. 2009;2(97):ra73 – reference: 21620138 - Cell. 2011 May 27;145(5):732-44 – reference: 21982705 - Cell Metab. 2011 Oct 5;14(4):443-51 – reference: 7810732 - Am J Physiol. 1994 Dec;267(6 Pt 2):H2325-32 – reference: 20451379 - Bioorg Med Chem Lett. 2010 Jun 1;20(11):3387-93 – reference: 1532331 - Crit Rev Oncog. 1992;3(1-2):91-115 |
| SSID | ssj0009580 |
| Score | 2.4808228 |
| Snippet | We show that the M2 isoform of pyruvate kinase (M2PYK) exists in equilibrium between monomers and tetramers regulated by allosteric binding of naturally... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 5881 |
| SubjectTerms | Allosteric Site Amino Acid Sequence Catalytic Domain Cell Line, Tumor Cell Proliferation Crystallography, X-Ray Dimerization Humans Inhibitory Concentration 50 Molecular Sequence Data Phenylalanine - chemistry Protein Conformation Protein Structure, Tertiary Pyruvate Kinase - metabolism Triiodothyronine - chemistry |
| Title | M2 pyruvate kinase provides a mechanism for nutrient sensing and regulation of cell proliferation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23530218 https://www.proquest.com/docview/1326143544 |
| Volume | 110 |
| WOSCitedRecordID | wos000317537900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qPHhR5-f8IoIHPQSbNh_NSUQcXjZ2UNitpG0iQ9fWdRv43_vSZuhFEIRSSqHlJXnJ-yV5-f0QuqIiBxAfagIzFEMgQsOTVoYYkwbahhEzTDdiE3I4jMdjNfILbrVPq1yNic1AnZeZWyO_hVmTcLGdsbvqgzjVKLe76iU01lEnAijjUrrkOP5Buhu3bASKEsFUsKL2kdFtVejaMStIyiWlwe_4sokz_Z3_WriLtj3CxPetS3TRmin2UNf34Rpfe6Lpm32kByGuPmeLJeBN_DYBWw32J_NqrPHUuFPBk3qKAdjiwtH2Q4TCtUt5L16xLnI8a5XsoW1xabHbBHA_eHfpMs3bA_TSf3x-eCJecoFkXAVzklkpUsEVlIVbCpcFSCdppnlKAwvo0EaOs54HhjmaGK5Ty2ORcw3II9NKhodooygLc4ywMNJYblMppGacWS1oysI8jKwKNM9kD12uqjEBl3Ym6sKUizr5rsgeOmrbIqla7o0kjJzMEY1P_vD1KdoKG_EKRgJ1hjoWOrQ5R5vZcj6pZxeNr8B9OBp8AVZDyXk |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=M2+pyruvate+kinase+provides+a+mechanism+for+nutrient+sensing+and+regulation+of+cell+proliferation&rft.jtitle=Proceedings+of+the+National+Academy+of+Sciences+-+PNAS&rft.au=Morgan%2C+Hugh+P&rft.au=O%27Reilly%2C+Francis+J&rft.au=Wear%2C+Martin+A&rft.au=O%27Neill%2C+J+Robert&rft.date=2013-04-09&rft.eissn=1091-6490&rft.volume=110&rft.issue=15&rft.spage=5881&rft_id=info:doi/10.1073%2Fpnas.1217157110&rft_id=info%3Apmid%2F23530218&rft_id=info%3Apmid%2F23530218&rft.externalDocID=23530218 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1091-6490&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1091-6490&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1091-6490&client=summon |